Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2023 May 5:13:1166545.
doi: 10.3389/fonc.2023.1166545. eCollection 2023.

Ongoing complete response after treatment cessation with dabrafenib, trametinib, and cetuximab as third-line treatment in a patient with advanced BRAFV600E mutated, microsatellite-stable colon cancer: A case report and literature review

Gudrun Piringer  1   2   3 , Jörn Decker  4 , Vera Trommet  1 , Thomas Kühr  1   3 , Sonja Heibl  1   3 , Konrad Dörfler  3 , Josef Thaler  1   3
Affiliations
Case Reports

Ongoing complete response after treatment cessation with dabrafenib, trametinib, and cetuximab as third-line treatment in a patient with advanced BRAFV600E mutated, microsatellite-stable colon cancer: A case report and literature review

Gudrun Piringer et al. Front Oncol. .

Abstract

Metastatic BRAFV600E mutated colorectal cancer is associated with poor overall survival and modest effectiveness to standard therapies. Furthermore, survival is influenced by the microsatellite status. Patients with microsatellite-stable and BRAFV600E mutated colorectal cancer have the worst prognosis under the wide range of genetic subgroups in colorectal cancer. Herein, we present a patient case of an impressive therapeutic efficacy of dabrafenib, trametinib, and cetuximab as later-line therapy in a 52-year-old woman with advanced BRAFV600E mutated, microsatellite-stable colon cancer. This patient achieved a complete response after 1 year of triple therapy. Due to skin toxicity grade 3 and recurrent urinary tract infections due to mucosal toxicity, a therapy de-escalation to dabrafenib and trametinib was performed, and the double therapy was administered for further 41 months with ongoing complete response. For 1 year, the patient was off therapy and is still in complete remission.

Keywords: BRAF-V600 mutation; MSS; combination targeted therapy; dabrafenib; trametinib.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Computed tomography scan (CT scan) regarding the clinical response during whole course of treatment. (A) Baseline CT scan in February 2017. (B) CT scan after adjuvant CAPOX in June 2017. (C) CT scan after 1 year of dabrafenib, trametinib, and cetuximab in October 2018.
Figure 2
Figure 2
Pronounced skin toxicity due to cetuximab therapy.
Figure 3
Figure 3
Flowchart of the whole course of treatment.
Figure 4
Figure 4
Line chart of the changes of the tumor marker CEA during the process of the treatment since February 2017. CEA, carcinoembryonic antigen.
See this image and copyright information in PMC

References

    1. Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, et al. . Mechanism of activation of the RAF ERK signaling pathway by oncogenic mutations of b-RAF. Cell (2004) 116:855–67. doi: 10.1016/S0092-8674(04)00215-6 - DOI - PubMed
    1. Barras D. BRAF mutation in colorectal cancer: an update. biomark Cancer (2015) 7:9–12. doi: 10.4137/BIC.S25248 - DOI - PMC - PubMed
    1. Davies H, Birgnell GR, Cox C, Stephens C, Edkins S, Clegg S, et al. . Mutations of the BRAF gene in human cancer. Nature (2002) 417:949–54. doi: 10.1038/nature00766 - DOI - PubMed
    1. Chu JE, Johnson B, Kugathasan L, Morris VK, Raghav K, Swanson L, et al. . Populations-based screening for BRAFV600E in metastatic colorectal cancer reveals increased prevalence and poor prognosis. Clin Cancer Res (2020) 26:4599. doi: 10.1158/1078-0432.CCR-20-1024 - DOI - PMC - PubMed
    1. Morris V, Overmann JM, Jiang ZQ, Garrett C, Agarwal S, Eng C, et al. . Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer. Clin Colorectal Cancer (2014) 13:164–71. doi: 10.1016/j.clcc.2014.06.001 - DOI - PMC - PubMed

Publication types